PP 8.4 – 00061 Bispecific antibodies promote natural killer cell-mediated elimination of the HIV reservoir

PP 8.4 – 00061 Bispecific antibodies promote natural killer cell-mediated elimination of the HIV reservoir

Bibliographic Details
Main Authors:	N. Board, F. Wu, M. Moskovljevic, M. Ravi, S. Sengupta, F. Simonetti, L. Montaner, S. Deeks, J. Siliciano, R. Siliciano
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664022002229

Similar Items

PP 4.8 – 00108 Presentation of cognate antigens by dendritic cells causes stochastic HIV expression
by: M. Moskovljevic, et al.
Published: (2022-12-01)

Understanding persistence of the latent reservoir
by: R.F. Siliciano
Published: (2017-12-01)

Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection
by: Ya-Chi Ho, et al.
Published: (2015-10-01)

Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.
by: Alison L Hill, et al.
Published: (2016-08-01)

Contribution of antigenic exposure to the persistence of HIV-infected CD4 T cells in vivo
by: F. Simonetti, et al.
Published: (2019-12-01)

Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir
by: Zheng Wang, et al.
Published: (2018-02-01)

HIV Prevention and Treatment Fields Join Forces
by: Steven G. Deeks, et al.
Published: (2014-11-01)

Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods.
by: Jennifer A White, et al.
Published: (2022-09-01)

HIV replication and evolution in patients on highly active antiretroviral therapy
by: Siliciano Robert F
Published: (2006-12-01)

OP 3.2 – 00056 Clonally expanded HIV-1 proviruses with 5′-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management
by: F. Wu, et al.
Published: (2022-12-01)

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
by: Natalie F. McMyn, et al.
Published: (2023-09-01)

Majority of the latent reservoir resides in CD32a negative CD4+ T cells
by: L.N. Bertagnolli, et al.
Published: (2017-12-01)

Low-level HIV-1 replication and the dynamics of the resting CD4<sup>+ </sup>T cell reservoir for HIV-1 in the setting of HAART
by: Wilke Claus O, et al.
Published: (2008-01-01)

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
by: M. Peluso, et al.
Published: (2019-12-01)

Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
by: Sulggi A Lee, et al.
Published: (2016-01-01)

OP 3.6 – 00023 Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation
by: J. Kufera, et al.
Published: (2022-12-01)

Measurement and characterization of the latent reservoir for HIV-1 in patients receiving solid organ transplant
by: A. Martin, et al.
Published: (2017-12-01)

OA1-1 Impact of vorinostat treatment of non-Hodgkin‘s lymphoma on HIV-1 latent reservoir
by: A. Capoferri, et al.
Published: (2017-07-01)

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
by: Hill, Alison Lynn, et al.
Published: (2015)

Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors
by: Yuan Yuan, et al.
Published: (2024-05-01)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017-04-01)

Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018-02-01)

Design and Production of Bispecific Antibodies
by: Qiong Wang, et al.
Published: (2019-08-01)

Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules
by: Justin Pollara, et al.
Published: (2020-04-01)

Tuberculosis – eliminating the latent killer
by: The Lancet Regional Health – Southeast Asia
Published: (2024-03-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV
by: A.L. Hill, et al.
Published: (2015-12-01)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01)

Production of native bispecific antibodies in rabbits.
by: Wei Wang, et al.
Published: (2010-01-01)

Bispecific Antibodies Progression in Malignant Melanoma
by: Juan Tang, et al.
Published: (2022-03-01)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01)

Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01)

PP 3.1 – 00058 Development of a digital PCR assay to profile HIV expression at single-infected-cell resolution
by: F. Dragoni, et al.
Published: (2022-12-01)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
by: Congcong Zhang, et al.
Published: (2021-10-01)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules
by: Marina Tuyishime, et al.
Published: (2021-08-01)

Next generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 reservoir size
by: M. Stone, et al.
Published: (2017-12-01)

Bispecific antibodies in indolent B-cell lymphomas
by: Vivek S. Radhakrishnan, et al.
Published: (2024-01-01)

Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
by: Ames C. Register, et al.
Published: (2021-05-01)

Immunotherapeutic progress and application of bispecific antibody in cancer
by: Jingyue Kang, et al.
Published: (2022-10-01)

Recent advances of bispecific antibodies in solid tumors
by: Shengnan Yu, et al.
Published: (2017-09-01)